# Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients

> **NCT01496339** · PHASE1,PHASE2 · UNKNOWN · sponsor: **S-Evans Biosciences Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** MenSCs transplantation
- **DRUG:** exogenous indulin injection daily

## Key facts

- **NCT ID:** NCT01496339
- **Lead sponsor:** S-Evans Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496339, "Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01496339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*